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Abstract
Nasopharyngeal carcinoma (NPC) is one of the most commons cancers in Southeast Asia and
Southern China. Several NPC-associated genes have been so far described and here we describe
the identification and the characterization of a novel nasopharyngeal carcinoma-associated peptide:
NAP-1. NAP-1 was identified with the human genome draft searching method combined with
nested PCR mapping of the chromosome 4q13 region. NAP-1 encodes an 85 amino acid alkaline
peptide with a calculated isoelectric point of 9.3, three phosphorilation sites and a proline-rich
region. Northern blot analysis revealed that NAP-1 is expressed as a 0.6 kb transcript in normal
lymph nodes and trachea. In addition, reverse transcription (RT)-PCR showed that NAP-1 is
expressed not only in NPC but in normal nasopharynx (NP) and various other tumors and tissues
of the head and neck including: tonsils, lymph nodes, carcinoma of the tonsil, T cell lymphomas,
squamous cell carcinoma of the hard palate, papilloma of the nasopharynx, nasopharyngitis,
lymphoma of the tongue root and follicular dendritic cells (FDC). In addition, NAP-1 is not
expressed in normal tissues or tumors from other anatomical regions and was not expressed by
NPC cell lines. Surprisingly, differential RT-PCR demonstrated decreased expression of NAP-1 in
NPC compared with paired NP biopsies in 42.5 % of cases (17 out of 40). In addition, in situ
hybridization and immunohistochemistry demonstrated that NAP-1 is expressed by S100+ CD35+
FDCs of the germinal center and not in other normal immune cells infiltrating NP or NPC.
Therefore, it is likely that NAP-1 is secreted by FDC in the NP and may play an immune modulatory
role in NPC.
Background
Nasopharyngeal carcinoma (NPC) is an endemic cancer
with high incidence in Southeast Asia and Southern China
with obvious inclination toward racial and geographic
influence. Epidemiological studies indicate that "three
hits and multiple steps" may be necessary for the develop-
ment of NPC. These include genetic predisposition,
Epstein – Barr virus (EBV) infection and environmental
conditions associated with dietary habits that may lead to
chemical carcinogenesis [1]. Among the genetic factors,
mutations leading to over expression of oncogenes such
as c-myc or H-ras or altered expression of tumor
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suppressor genes such as p53 and p16 have been
described [2]. However, to these days there is no conclu-
sive molecular understanding of the pathogenesis of NPC
and the quest for relevant associations between gene
expression patterns in this disease remains relevant.
For this reason we queried available data bases for the
identification of putative genetic associations with NPC.
By exploring UniGene we could partition GeneBank
sequences according to gene-oriented clusters that segre-
gate genes according to their expression in various tissues
or diseases. At the same time clusters can be created based
on sequence homology at the genomic or transcriptional
level. Consequently each UniGene cluster contains
sequences most likely to represent a unique gene and
information about its tissue distribution. Often expres-
sion sequence tags (EST) are identified for which no anno-
tation is available and by assembling available
information. It is sometimes possible to perform an elec-
tronic prolongation of the relevant EST to construct a
putative gene identity. Traditional cDNA library screening
can subsequently offer the opportunity to expand knowl-
edge on the identified genes by utilizing information col-
lected from various data bases. Therefore, we utilized this
Human Genome Searching Method combined with
nested PCR to extend available sequence information on
genes of putative interest with particular focus on the
characterization of the 5' end and/or the full length of
available cDNA libraries [3]. In this fashion, an EST contig
was obtained from which a gene associated with NPC was
characterized. The gene was named nasopharyngeal carci-
noma-associated peptide (NAP)-1 and characterization of
its pattern of expression in normal and cancerous tissues
was undertaken.
Results
A search was performed on the UniGene data base query-
ing for Homo. sapiens nasopharynx. Thirty seven NP-
related UniGene clusters were identified. Sixteen of the 37
clusters contained novel not previously annotated
sequences. Among those we focused our attention on 4
ESTs (BG222624 mapped chromosome to 5q, BG231276
mapped to 2p, BG231174 mapped to 3p and BG231197
mapped to 4q) located in chromosomal areas in which a
high frequency of amplifications or deletions have been
reported [4-6]. No differential expression between NPC
and paired NP specimens could be observed by RT-PCR
for three ESTs (BG222624, BG231276, BG231174) while
differences were noted for the one mapped on chromo-
some 4q.
Therefore, we focused our attention an the latter gene and
an EST contig (502 bp) was assembled by combining
information from 4 highly homologous ESTs (GenBank
accession number CB140082, AI332560, BG059093 and
AI701589) according to EST BLAST searches using a cDNA
fragment (GenBank accession number BG231197) as
electronic probe. Electronic prolongation by EST contig
did not reveal a complete open reading frame. Bioinfor-
matics analysis suggested the contig resembled a human
peptide precursor secreted by follicular dendritic cells
(FDC-SP) (GenBank accession number AF435080) [10]
with a 77% homology. No stop codons in frame with the
cDNA 5' end start codon of the FDC-SP could be identi-
fied. The results suggested that the full-length cDNAs
could be obtained by combining the Human Genome
Draft Searching Method with nested PCR (Figure 1a).
Northern blot analysis revealed that the gene produced a
transcript (0.6 kb) that could be identified among normal
tissues only in lymph nodes and trachea (Figure 1b).
We named the novel gene nasopharyngeal carcinoma-
associated peptide (NAP-1; GenBank Accession number
AY190326). The length of NAP-1 cDNA is 573 bp with an
ORF from 113 bp to 370 bp. NAP-1 encodes a 9,700 Dal-
ton protein composed of 85 amino acids. The predicted
amino acid sequence of the NAP-1 protein is:
MKKVLLLITAILAVAVGFPVSQDQEREKRSISDSDELASGF
FVFPYPYPFRPLPPIPFPRFPWFRRNFPIPIPESAPT-
TPLPSEK. NAP-1 maps in chromosome 4q13 and the
genomic sequence spans 9,179 bp that include 5 exons
and 4 introns (Table 1). No other genes homologous to
NAP-1 could be identified. Bioinformatics analysis indi-
cated that NAP-1 is a alkaline protein with a theoretic iso-
electric point of 9.3. The protein is most likely secreted
and has 3 phosphorylation sites and 1 proline-rich region.
Differential RT-PCR results suggested that NAP-1 is
expressed in NP, NPC, tonsil, lymph node, carcinoma of
the tonsil, T-cell lymphoma, squamous cell carcinoma of
the hard palate, papilloma of the nasopharynx, chronic
nasopharyngitis, lymphoma of the base of the tongue and
FDC lines. NAP-1 expression was not found in other nor-
mal or tumor biopsies nor in NPC cell lines. (Table 2).
These results suggest that NAP-1 gene maybe expressed in
immune cells of the NP and in NPC stroma. In addition,
differential RT-PCR analysis revealed decreased expres-
sion of NAP-1 in 17 of 40 NPC compared with paired NP
specimens (42.5%). In 6 cases (15%) NAP-1 expression
was higher in NPC compared with NP while there was no
difference in expression in the remaining 17 cases (42.5%,
Table 3). Possibly, different patterns of expression could
be related to the immune status of individual NPC.
In situ hybridization and immunohistochemistry sug-
gested that the NAP-1 peptide is expressed in S100+
CD35+ FDC of the germinal center and not in other stro-
mal immune cells in NPC and NP tissues (Figure 2). RT-
PCR, Western Blotting, immunohistochemistry and in
situ hybridization of FDC lines further demonstrated thatJournal of Translational Medicine 2004, 2 http://www.translational-medicine.com/content/2/1/10
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NAP-1 is a protein specifically secreted by these cells (Fig-
ure 3).
Discussion
Several NPC-associated genes have been described in the
past. In this study, we describe the identification of a
novel NPC-associated peptide that we called NAP-1. NAP-
1 was identified searching the human genome data based
and confirmed in histologically confirmed NP biopsies
using nested PCR. Northern blot analysis revealed that
NAP-1 is expressed only in lymph node and trachea
among all the normal tissues tested (not in heart, brain,
placenta, lung, liver, skeletal muscle, kidney, pancreas,
stomach, thyroid, spinal cord, adrenal gland and bone
marrow). This result was concordant with RT-PCR analy-
sis that identified NAP-1 expression in normal, inflamed
or cancerous nasopharynx biopsies but not in other nor-
mal or cancerous biopsies. In addition, since NAP-1 was
found to be expressed by FDC but not NPC cell lines it is
likely that this peptide is a component of the immune
response in NP and may play a modulatory role in the
context of NPC. Indeed, common markers for dendritic
cells in tumor stroma such as S100 or specific for FDC
such CD35 suggest specific expression of NAP-1 by these
cells [11-13] as both in situ hybridization and immuno-
histochemistry pointed to its expression by S100+ CD35+
FDC and not in other stromal immune cells either in NP
or NPC tissues (Figure 2). Interestingly, NAP-1 was not
observed in the spleen but its expression was noted in the
trachea. Since spleen tissue contains mostly primary folli-
cles, we favor the hypothesis that NAP-1 expression is low
or absent in primary follicles but is up-regulated in the fol-
licles during germinal center formation by activated FDC,
which are present in primary and secondary follicles [14-
16]. FDC are present mainly in the germinal center of
lymph node paracortex but they can also be found in the
germinal center of follicles in mucosa-associated lym-
phoid tissues such as tonsils and dispersion lymph tissue
in other parts of the pharynx. A distinctive characteristic of
FDCs is the ability to trap immune complexes and act as
antigen depots during the germinal center response. FDCs
play a central role in organization of the follicular struc-
ture that supports B cell survival, affinity maturation of
antibody responses and the generation of long-lived B cell
memory [17-19]. Our results suggest that NAP-1 is
secreted by FDC and may modulate lymphoid and pre-
sumably modulate directly or indirectly NPC cancer cell
growth. Thus, expression of NAP-1 may be related to the
local immune status of NPC although it's function(s)
remains unknown.
Western blotting on FDC lines demonstrated that the
NAP-1 protein is secreted by FDC although definitive
sequencing of the gene product detected in FDC superna-
tants was beyond the scope of this study. In addition, we
are planning to test whether NAP-1 expression is exclu-
sively restricted to FDC or other antigen presenting cells
such as monocyte derived DC activated in vitro could also
express NAP-1. It is possible that NAP-1 could be a marker
of the status of function of monocytes, immature or
matured DC [20-22]. This hypothesis should be tested in
the future since it may also provide an easier reagent to
Cloning and identification of NAP-1 gene Figure 1
Cloning and identification of NAP-1 gene A: Identifi-
cation of 5' end's PCR product of the gene by using 
human genome draft searching methodcombined 
with nested PCR 1. pFRW-2 and pRVS-3(no); 2. pFRW-2 
and pRVS-2(no); 3. pFRW-3 and pRVS-3(176 bp); 4. pFRW-3 
and pRVS-2(282 bp) M: DNA ladder B: Northern blots 
analysis of the gene in 15 kinds of human tissues 1. 
heart; 2. brain; 3. placenta; 4. lung; 5. liver; 6. skeletal muscle; 
7. kidney; 8. pancreas; 9. stomach; 10. thyroid; 11. spinal 
cord; 12. lymph node; 13. trachea; 14. adrenal gland; 15. bone 
marrowJournal of Translational Medicine 2004, 2 http://www.translational-medicine.com/content/2/1/10
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study the relationship between immune and NPC cells in
different in vitro or in vivo models.
We did not find point mutations and other aberrations in
the coding region of the NAP-1 gene by PCR-SSCP (data
not shown). In addition, analysis of the NAP-1 gene
genomic region did not identified possible CpG island in
the 5' non-coding region of NAP-1. Therefore, we believe
that decreased expression of NAP-1 in NPC compare with
NP represents more a physiopathological fluctuation in
the number and function of FDC that populate various
NPC biopsies.
Conclusions
In summary, NAP-1 is a protein probably secreted by
FDC. NAP-1 might only be expressed in FDC of tonsil,
lymph node, tonsil carcinoma, lymphoma, NPC and NP
tissue stroma. Its expression is decreased in NPC com-
pared with paired NP biopsies and this differential expres-
sion may be associated with local immune status of NPC.
Methods
GeneBank data searching and EST assembly
Gene identifications were on UniGene querying for Homo.
sapiens nasopharynx. Among genes possibly newly associ-
ated with NP we focus on those that resided in chromo-
somal regions frequency characterized by amplification or
deletion in the context of NPC [4-6]. EST contigs where
then assembled according to homology ranking according
to BLAST searches using a cDNA-based electronic probe.
Tissue samples, cells, cell culture and RNA extract
NPC and paired NP biopsies were obtained at Xiangya
Hospital, Central South University, Changsha, China.
Other normal and tumor biopsies were also obtained at
Xiangya Hospital and included: tonsil, lymph node, carci-
noma of the tonsil, carcinoma of the larynx, T-cell lym-
phoma, carcinoma of the hypo-pharynx, squamous cell
carcinoma of the hard palate, papilloma of the nasophar-
ynx, chronic naso-pharyngitis, lymphoma of the base of
the tongue, chronically inflamed vocal cords, carcinoma
of the epiglottis, cerebral glioma, normal lung, lung can-
cer, liver, liver cancer, kidney, ileum, stomach, stomach
Table 1: Exon-intron junctions of the NAP-1 gene
Exon Exon size(bp) 5'splice donor Intron size(bp) 3'splice acceptor Intron
1 112 TTTGAGgtaaga 5012 1
2 57 TTCCCAgtaagt 1742 ttgcagATGAAG 2
3 33 AGAAGTgtaagt 993 ctttagGTCTCT 3
41 9 6 A A C C T G gtaagt 869 caacagATCAGT 4
5 165 tttcagGTCACC
Uppercase and lowercase letters indicate exon and intron sequences respectively. Conserved splice donor and acceptor dinucleotide sequences 
are indicated in bold.
Table 2: Expression in other normal, tumor biopsies and cell lines by differential RT-PCR
case number & specimen IA case number & specimen IA
1 tonsil 0.78 2 lymph node 1.00
3 tonsil carcinoma 0.45 4 T- cell lymphoma 0.86
5 tongue root lymphoma 0.35 6 hard palate squamous cell 
carcinoma
0.39
7 nasopharynx papilloma 0.17 8 chronic nasopharyngitis 0.59
9 follicular dendritic cell line 1.02 10 chronic inflammation of vocal 
cords
0.00
11 larynx carcinoma 0.00 12 epiglottis carcinoma 0.00
13 hypopharynx carcinoma 0.00 14 cerebra 0.00
15 glioma 0.00 16 ileum 0.00
17 liver, liver cancer 0.00 18 kidney 0.00
19 stomach, stomach cancer 0.00 20 parotid, spleen 0.00
21 fetal heart, uterus 0.00 22 rectum, rectal cancer 0.00
23 CNE-1 0.00 24 CNE-2 0.00
25 HNE-3 0.00 26 5–8F 0.00Journal of Translational Medicine 2004, 2 http://www.translational-medicine.com/content/2/1/10
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cancer, parotid, spleen, fetal heart, uterus, rectum and rec-
tal cancer. The taxonomy of all samples was confirmed by
histological examination. The NPC cell lines, CNE-1,
CNE-2, HNE-3 and B95-8F were obtained from the Can-
cer Research Institute, Xiangya School of Medicine, Cen-
tral South University. NPC cell lines were maintained in
RPMI 1640 medium supplemented with 10% FBS, 50,000
units lit.-1 Penicillin, streptomycin 50 mg lit.-1 at 37°C, in
humidified conditions at 5 % CO2 and 95 % air [4-6]. Fol-
licular dendritic cells lines (HK cells) were kindly pro-
vided by Choi YS from the Cancer Research Institute of
The First Military Medical University of China. FDC line
were cultured by the method as described by Dr. Choi YS
[7-9]. Total RNA was extracted from biopsy specimens
and cell lines using Trizol reagent (Gibco/BRL Life Tech-
nologies, Inc., Gaithersburg, MD, USA).
Differential RT-PCR
Total RNA was digested by RNase-free DnaseI (Roche
Diagnostics Corporation, Indianapoils, IN, USA), 37°C, 1
hours. The reaction product was dissolved in double dis-
tilled water treated by DEPC. RNA was diluted to 200 µl,
wiped off protein with Trizol, and finally dissolved in
double distilled water treated by DEPC. For RT-PCR total
RNA was reversed transcribed using a commercially avail-
able Reverse Transcription System (Promega Corporation,
Madison WI, USA). A 20 µl reaction was prepared by add-
ing MgCl2 (25 mM) 4 µl, 10 × Buffer 2 µl, dNTPs(10 mM)
2 µl, RNasin (40U/µl) 0.5 µl, AMV reverse enzyme (24 U/
µl) 0.6 µL, Oligo (dT) 1 µl, RNA 2 µg. The reaction was
performed at 42°C for 30 minutes followed by heating at
99°C for 5 minutes and incubation at 0–5°C for 5 min-
utes. The resulting cDNA samples were subjected to PCR
amplification using NAP-1's specific primers CAGCGTCA-
GAGAGAAAGAAC and GTGTGCTATTTCAATTACATTTG
(pFRW-1/pRVS-1) or GAPDH control primers
AAGCCCATCACCATCTTCCA and CCTGCTTCACCAC-
CTTCTTG. 2 µl 10 × PCR reaction buffer, 0.4 µl Taq DNA
polymerase(3U/ µl) (TaKaRa Bio Inc., Otsu, Shiga, Japan),
0.4 µl dNTPs(10 mM), 0.2 µL 20 µM pFRW, 0.2 µl 20 µM
pRVS, 0.8 µl biopsies or cells' cDNA were contained in a
20 µl amplification reaction. Amplifications were carried
out in a Biometra thermal cycler with the following pro-
gram: 95°C for 5 minutes, 32 cycles of 94°C for 40 sec-
onds, 58°C for 30 seconds, 72°C for 50 seconds and a
final extension at 72°C for 5 minutes. The resulting PCR
products were run on agarose gels and stained with ethid-
ium bromide.
Grey-scale scanning and data analysis
The resulting PCR products were scanned by a Gel Scanner
(Pharmacia Biotech, Inc., Piscataway, NJ, USA). Scanning
integral absorption of PCR products (IA) was measured by
Imagemaster VDS Image Analysis Software normalizing
the data with GADPH internal control amplicons. The
ratio of NP (IA) over GAPDH (IA) is represented as N(IA).
The ratio of NPC (IA) over GAPDH (IA) is represented as
T(IA). NAP-1 gene expression was considered low in NPC
Expression of NAP1 gene in S100+ CD35+ FDC of germinal  center not in other stromal immune cells of NP and NPC  biopsies Figure 2
Expression of NAP1 gene in S100+ CD35+ FDC of ger-
minal center not in other stromal immune cells of 
NP and NPC biopsies. A: In situ hybridization by Dig 
labelled NAP-1 cDNA probe in NP biopsies (×300); B: Immu-
nohistochemistry by Mouse Anti-S100 Monoclonal antibody 
in NP biopsies (×300); C: In situ hybridization by Dig labelled 
NAP-1 cDNA probe in NPC biopsies (×300); D: Immunohis-
tochemistry by Mouse Anti-S100 Monoclonal antibody in 
NPC biopsies (×300); E: In situ hybridization by Dig labelled 
NAP-1 cDNA probe in NP biopsies (×300); F: Immunohisto-
chemistry by Mouse Anti-CD35 Monoclonal antibody in NP 
biopsies (×300); G: In situ hybridization by Dig labelled NAP-
1 cDNA probe in NPC biopsies (×300); H: Immunohisto-
chemistry by Mouse Anti-CD35 Monoclonal antibody in 
NPC biopsies (×300)Journal of Translational Medicine 2004, 2 http://www.translational-medicine.com/content/2/1/10
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if T(IA) over N(IA) was less than 0.5. Conversely,
increased expression was considered a T(IA) / N(IA) ratio
above 2. As a consequence no significant differences in
expression between NPC and NP were included between
T(IA) / N(IA) ration bigger than 0.5 and lower than 2.
Human Genome Draft Searching Method
The NAP-1 gene cDNA was identified from NP biopsies
combining information derived through the Human
Genome Draft Searching Method combined with nested
PCR [3]. As a large-scale sequencing fragment could be
identified in Human Genome Draft corresponding to the
EST contig, we searched for stop codons in frame with the
contig starting codon in the sequencing fragment
upstream of the contig 5' end. Two forward primers were
designed flanking the stop codon (pFRW-2, GATTTTGG-
TATTTGGTAGTTTC; pFRW-3, CTCCATTCCATTATAC-
CTTTGAG) and two reverse primers were designed
flanking the contig start codon (pRVS-3, GAGAGACT-
GGGAAACCAACAG; pRVS-2, GGAATTGGTGGAAGT-
GGGCGA). The fragment was amplified by PCR from
cDNA of NP biopsies. Primers pFRW-2/ pRVS-3, pFRW-2/
pRVS-2, pFRW-3/ pRVS-3, and pFRW-3/ pRVS-2 were used
for PCR amplifications. Amplifications were carried out in
a Biometra thermal cycler according to the following pro-
gram: 95°C for 3 minutes, 30 cycles of 94°C for 40
seconds,60°C for 30 seconds, 72°C for 50 seconds and a
final extension at 72°C for 5 minutes. The resulting PCR
products were run on agarose gels and stained with ethid-
ium bromide. The theoretical sizes of PCR products pre-
dicted according to Human Genome Draft Searching
Method were 176 bp (pFRW-3/ pRVS-3), 282 bp (pFRW-
3/pRVS-2), 296 bp (pFRW-2/ pRVS-3) and 402 bp
(pFRW-2/ pRVS-2) respectively. Gene identity was con-
firmed by concordance of predicted and actual amplicon
size.
Northern Blot and Western blotting analysis
The probe for Northern Blot was prepared by PCR ampli-
fication of the pUCm-T/ NAP-1 plasmid and labeled using
α-32P-dCTP using the Prime-a-Gene Labeling System
(Promega Corporation, Madison, WI, USA). The
radioactivity of the probe is bigger than 1 × 108cpm/ µg.
The probe was purified by Sephadex G-50 column and
hybridized to human tissues according to a standard
Northern blot procedure (Cat.7760-1 and Cat.7767-1, BD
Biosciences Clontech, Palo Alto, CA, USA) using
ExpressHyb™ Hybridization Solution (Cat.636831, BD
Biosciences Clontech, Palo Alto, CA, USA).
Rabbit Anti-NAP-1 polyclonal antibody was prepared by
Wuhan Boster Biological Technology Ltd., Wuhan, Hubei,
China based on the N-terminus peptide sequence of the
NAP-1 protein: GFPVSQDQEREKRSI.
The Phototope®-HRP Western Blot Detection Kit (New
England Biolabs Inc., Beverly, MA, USA) was adopted for
Immunoblotting analysis in FDC lines culture superna-
Table 3: Expression difference between NPC and NP biopsies by differential RT-PCR in 40 cases
case number N(IA) T(IA) T(IA) / N(IA) case number N(IA) T(IA) T(IA) / N(IA)
1 2.77 0.06 0.02 2 0.68 0.00 0.00
3 3.33 0.40 0.12 4 0.13 0.08 0.61
5 4.03 2.30 0.57 6 2.86 0.00 0.00
7 0.47 0.00 0.00 8 0.01 0.98 98.00
9 1.43 1.72 1.20 10 0.88 1.84 2.09
11 0.81 0.56 0.70 12 0.89 0.30 0.34
13 0.93 0.98 1.03 14 0.01 0.70 70.00
15 1.06 0.16 0.15 16 0.71 0.46 0.65
17 0.08 0.26 3.25 18 2.48 0.01 0.00
19 0.16 0.30 1.88 20 1.60 0.48 0.30
21 1.16 0.46 0.40 22 0.53 0.61 1.15
23 0.50 0.32 0.64 24 1.88 0.68 0.36
25 0.83 0.82 0.99 26 0.60 0.00 0.00
27 5.34 5.50 1.03 28 8.01 0.45 0.06
29 0.86 0.73 0.85 30 1.03 3.09 3.00
31 1.07 0.97 0.91 32 0.81 1.20 1.48
33 1.36 0.18 0.13 34 0.12 0.27 2.25
35 0.25 0.00 0.00 36 0.06 0.00 0.00
37 0.27 0.17 0.63 38 0.01 0.00 0.00
39 0.68 0.47 0.69 40 0.44 0.75 1.70
IA : Integral absorption of PCR products; N(IA): IA(N)/ IA (GAPDH); T(IA) :IA(T)/ IA (GAPDH); T(IA) / N(IA) < 0.5: expression decreased; T(IA) / 
N(IA) > 2: expression increased; 0.5< T(IA) / N(IA) < 2: no expression differenceJournal of Translational Medicine 2004, 2 http://www.translational-medicine.com/content/2/1/10
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tants. Supernatants were collected after one and two days
of FDC culture. Supernatants were concentrated by vac-
uum evaporation and collected according to a commercial
Western Blot Detection Kit protocol. Protein samples and
molecular weight standards were separated by polyacryla-
mide gel electrophoresis. The proteins were transferred to
a nitrocellulose (NC) membrane by electroblotting and
blocked to saturate nonspecific binding sites on the mem-
brane. The membrane was incubated with the primary
rabbit anti-NAP-1 polyclonal antibody followed by incu-
bation with HRP-linked anti-rabbit IgG. LumiGLO™ rea-
gent was then added and the emission was captured on X-
ray films. NC membranes with the primary antibody
replaced with block solution were used as negative con-
trols. Fresh culture media was used as negative control for
the supernatants.
In situ hybridization and Immunohistochemistry
NP and NPC biopsies were immediately fixed following
surgical excision to prevent degradation of messenger
RNA. The tissues were incubated at 4°C for 2–4 hours
with freshly made, filtered fixative (DEPC-treated PBS
containing 4% paraformaldehyde; pH 7.5) and stored in
a freezing compound at -80°C. Samples were then
warmed to -20°Cm cut in 10 µm sections in a cryostat and
placed on pretreated glass slides for analysis. The slides
were Dried in an oven at 40°C overnight and used imme-
diately or stored in a box at -80°C. Before processing, the
stored slides were warmed at room temperature and dries
in an oven at 40°C for a minimum of 2 hours.
FDC cells were cultured at 37°C in a 5% CO2 atmosphere
on poly-L-lysine coated microscopic slides in Dulbecco's
minimal essential medium without phenol red. Cells
were washed with PBS at 37°C and fixed at room temper-
ature for 30 minutes in a 4% (w/v) formaldehyde, 5% (v/
v) acetic acid, and 0.9% (w/v) NaCl solution. Fixed cells
were washed with PBS at room temperature and stored in
70% ethanol at 4°C.
In situ hybridization was performed according to the Dig
DNA Labelling and Detection Kit's protocol (Boehringer
Mannheim Gmbh Biochemica, Mannheim, Allemagne,
Germany). Briefly, a NAP-1 specific cDNA probe was pre-
pared by PCR DIG Probe Synthesis. The prepared tissue
sections and FDC cells on slides were treated with protei-
nase K (Sigma-Aldrich Corporation., Saint Louis, MO),
washed, pre-hybridized, and then hybridized overnight at
50°C with 20 µl hybridization buffer containing 30 ng
DIG-Labeled probe. After hybridization, slides were
rinsed, and washed twice with 2 × SSC, 1 × SSC and 0.1 ×
SSC at 50°C for 15 minutes each. After washing, the slides
were stained with Fast Red if need. Hybridization buffer
containing no DIG-Labeled probe was used as negative
control.
The primary CD35, CD3, CD20, CD57, CD68, S-100
monoclonal antibodies (Zymed Laboratories, Inc., South
San Francisco, CA) and the rabbit Anti-NAP-1 polyclonal
antibody were used for Immunohistochemistry. The "two
steps" system (Antibody Diagnostica Inc., Stamford, CT)
was used. The slides were incubated with 3% H2O2 at
room temperature for 10 minutes to inactivate internal
enzymes and then washed with PBS (pH7.6). Normal
sheep serum was added in droplets. Primary antibodies
were diluted with PBS (1 : 50) and added to the slides,
NAP-1 protein is a secreted protein secreted by FDC Figure 3
NAP-1 protein is a secreted protein secreted by 
FDC. A: NAP-1 gene is expressed in S100+ CD35+ 
FDC cell lines 1. In situ hybridization by Dig labelled NAP-1 
cDNA probe in FDC lines (×300); 2. Immunohistochemistry 
by Mouse Anti-S100 Monoclonal antibody in FDC lines 
(×300); 3. Immunohistochemistry by Mouse Anti-CD35 
Monoclonal antibody in FDC lines (×300); 4. Immunohisto-
chemistry by Rabbit Anti-NAP-1 polyclonal antibody in FDC 
lines (×300) B: Western blotting analysis of FDC cul-
ture supernatants using rabbit anti-NAP-1 polyclonal 
antibody 1. The negative antibody control: the primary anti-
body replaced with block solution; 2. The negative superna-
tants control: the FDC lines culture supernatants replaced 
with fresh media; 3. Western blotting analysis of FDC super-
natants cultured for 1 day; 4. Western blotting analysis of 
FDC supernatants cultured for 2 daysPublish with BioMed Central    and   every 
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which were then placed in the refrigerator (4°C) over-
night. Then, the HRP-linked anti-rabbit IgG or HRP-
linked anti-mouse IgG (Antibody Diagnostica Inc.) were
added. Slides were incubated at 37°C for 40 minutes and
then washed 3 times after each step for 5 minutes. Then
the slides were stained with DAB enzyme for 5–30 min-
utes, dehydrated, made transparent with dimethylben-
zene and sealed with neutral gum. They were then
visualized under a microscope. Slide with the primary
antibody replaced with PBS were used as the negative
control.
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